· On Dec. 8, the U.S. Food and Drug Administration (FDA) approved:
· Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for treatment and control of bleeding episodes in adults diagnosed with VWD. Read more.
· Kanuma (sebelipase alfa) as the first treatment for patients with lysosomal acid lipase (LAL) deficiency. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.